List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7466284/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer. New England Journal of Medicine, 2002, 347, 1233-1241.	27.0	5,366
2	Twenty-Five-Year Follow-up of a Randomized Trial Comparing Radical Mastectomy, Total Mastectomy, and Total Mastectomy Followed by Irradiation. New England Journal of Medicine, 2002, 347, 567-575.	27.0	1,213
3	Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. Journal of Clinical Oncology, 2014, 32, 3744-3752.	1.6	771
4	Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31. Journal of Clinical Oncology, 2011, 29, 3366-3373.	1.6	646
5	Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer, Journal of Clinical Oncology, 2012, 30, 3792-3799.	1.6	446
6	Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Five National Surgical Adjuvant Breast and Bowel Project Node-Positive Adjuvant Breast Cancer Trials. Journal of Clinical Oncology, 2006, 24, 2028-2037.	1.6	418
7	Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer. Journal of Clinical Oncology, 2009, 27, 2466-2473.	1.6	397
8	Patterns of Locoregional Failure in Patients With Operable Breast Cancer Treated by Mastectomy and Adjuvant Chemotherapy With or Without Tamoxifen and Without Radiotherapy: Results From Five National Surgical Adjuvant Breast and Bowel Project Randomized Clinical Trials. Journal of Clinical Oncology, 2004, 22, 4247-4254.	1.6	348
9	Overexpression of Glutâ€1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer, 2003, 97, 1015-1024.	4.1	336
10	Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet, The, 2004, 364, 858-868.	13.7	334
11	Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial. Journal of Clinical Oncology, 2008, 26, 1965-1971.	1.6	317
12	Longer Therapy, latrogenic Amenorrhea, and Survival in Early Breast Cancer. New England Journal of Medicine, 2010, 362, 2053-2065.	27.0	292
13	Population-Based Study of Competing Mortality in Head and Neck Cancer. Journal of Clinical Oncology, 2011, 29, 3503-3509.	1.6	172
14	Breast Cancer Adjuvant Therapy: Time to Consider Its Time-Dependent Effects. Journal of Clinical Oncology, 2011, 29, 2301-2304.	1.6	151
15	21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy. Journal of the National Cancer Institute, 2017, 109, djw259.	6.3	116
16	Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG) Tj ETQq0 0 0 r The, 2019, 20, 88-99.	gBT /Overlo 10.7	ock 10 Tf 50 108
17	Intrinsic Subtypes, <i>PIK3CA</i> Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial. Journal of Clinical Oncology, 2015, 33, 1340-1347.	1.6	105

Low Locoregional Recurrence Rate Among Node-Negative Breast Cancer Patients With Tumors 5 cm or Larger Treated by Mastectomy, With or Without Adjuvant Systemic Therapy and Without Radiotherapy: Results From Five National Surgical Adjuvant Breast and Bowel Project Randomized Clinical Trials. Journal of Clinical Oncology, 2006, 24, 3927-3932.

#	Article	IF	CITATIONS
19	Association of Polymorphisms in <i>FCGR2A</i> and <i>FCGR3A</i> With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer. JAMA Oncology, 2017, 3, 335.	7.1	96
20	Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31. Journal of the National Cancer Institute, 2013, 105, 1782-1788.	6.3	94
21	Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity. Oral Oncology, 2007, 43, 796-803.	1.5	83
22	Evaluation of Microtubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial. Journal of Clinical Oncology, 2009, 27, 4287-4292.	1.6	81
23	Parametric regression on cumulative incidence function. Biostatistics, 2007, 8, 184-196.	1.5	78
24	Treatment of Axillary Lymph Node-Negative, Estrogen Receptor-Negative Breast Cancer: Updated Findings From National Surgical Adjuvant Breast and Bowel Project Clinical Trials. Journal of the National Cancer Institute, 2004, 96, 1823-1831.	6.3	76
25	Detection of recurrent oral squamous cell carcinoma by [18F]-2-fluorodeoxyglucose-positron emission tomography. Cancer, 2003, 98, 2257-2265.	4.1	63
26	Direct parametric inference for the cumulative incidence function. Journal of the Royal Statistical Society Series C: Applied Statistics, 2006, 55, 187-200.	1.0	62
27	Amenorrhea from Breast Cancer Therapy — Not a Matter of Dose. New England Journal of Medicine, 2010, 363, 2268-2270.	27.0	61
28	Pitfalls of Using Composite Primary End Points in the Presence of Competing Risks. Journal of Clinical Oncology, 2010, 28, 4297-4299.	1.6	61
29	Safety and utilization of peripherally inserted central catheters versus midline catheters at a large academic medical center. American Journal of Infection Control, 2016, 44, 1458-1461.	2.3	60
30	Evaluation of spontaneous propulsive movement as a screening tool to detect rescue of Parkinsonism phenotypes in zebrafish models. Neurobiology of Disease, 2011, 44, 9-18.	4.4	55
31	Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth	1.6	55
32	Akt Phosphorylation at Ser473 Predicts Benefit of Paclitaxel Chemotherapy in Node-Positive Breast Cancer. Journal of Clinical Oncology, 2010, 28, 2974-2981.	1.6	54
33	Nonparametric Inference on Median Residual Life Function. Biometrics, 2008, 64, 157-163.	1.4	49
34	A new generalization of Weibull distribution with application to a breast cancer data set. Statistics in Medicine, 2009, 28, 2077-2094.	1.6	49
35	Predictors of competing mortality in early breast cancer. Cancer, 2010, 116, 5365-5373.	4.1	36
36	NSABP B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared with Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor—Positive Breast Cancer. Clinical Breast Cancer, 2006, 7, 416-421.	2.4	35

#	Article	IF	CITATIONS
37	Statistical Modelling of Survival Data with Random Effects. Statistics in the Health Sciences, 2017, , .	0.2	35
38	Regression on Quantile Residual Life. Biometrics, 2009, 65, 1203-1212.	1.4	34
39	Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 51-59.	2.5	33
40	Rank tests for clustered survival data. Lifetime Data Analysis, 2003, 9, 21-33.	0.9	28
41	The Influence of Knee Pain Location on Symptoms, Functional Status, and Knee-related Quality of Life in Older Adults With Chronic Knee Pain. Clinical Journal of Pain, 2016, 32, 463-470.	1.9	28
42	An Isoform of C/EBPβ, LIP, Regulates Expression of the Chemokine Receptor CXCR4 and Modulates Breast Cancer Cell Migration*. Journal of Biological Chemistry, 2013, 288, 28656-28667.	3.4	27
43	Analysis of clustered competing risks data using subdistribution hazard models with multivariate frailties. Statistical Methods in Medical Research, 2016, 25, 2488-2505.	1.5	27
44	A first look at the Accreditation Council for Graduate Medical Education anesthesiology milestones: implementation of self-evaluation in a large residency program. Journal of Clinical Anesthesia, 2016, 32, 17-24.	1.6	22
45	Hierarchical likelihood inference on clustered competing risks data. Statistics in Medicine, 2016, 35, 251-267.	1.6	21
46	Variable selection in subdistribution hazard frailty models with competing risks data. Statistics in Medicine, 2014, 33, 4590-4604.	1.6	19
47	Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy. Journal of the National Cancer Institute, 2016, 108, djv304.	6.3	19
48	A new parametric family for modelling cumulative incidence functions: application to breast cancer data. Journal of the Royal Statistical Society Series A: Statistics in Society, 2006, 169, 289-303.	1.1	18
49	Clinical and prognostic value of [18F]FDG-PET for surveillance of oral squamous cell carcinoma after surgical salvage therapy. Oral Oncology, 2006, 42, 297-305.	1.5	18
50	Frailty models and rank tests. , 1998, 4, 209-228.		17
51	Constrained parametric model for simultaneous inference of two cumulative incidence functions. Biometrical Journal, 2013, 55, 82-96.	1.0	17
52	A Standardized Obstacle Course for Assessment of Visual Function in Ultra Low Vision and Artificial Vision. Journal of Visualized Experiments, 2014, , e51205.	0.3	17
53	Empirical likelihood ratio test for median and mean residual lifetime. Statistics in Medicine, 2011, 30, 152-159.	1.6	16
54	Statistical Inference on Residual Life. Statistics in the Health Sciences, 2014, , .	0.2	15

#	Article	IF	CITATIONS
55	Rank tests for clustered survival data when dependent subunits are randomized. Statistics in Medicine, 2006, 25, 361-373.	1.6	13
56	Censored quantile regression for residual lifetimes. Lifetime Data Analysis, 2012, 18, 177-194.	0.9	13
57	Deep learning for quantile regression under right censoring: DeepQuantreg. Computational Statistics and Data Analysis, 2022, 165, 107323.	1.2	13
58	Low-Fidelity Haptic Simulation Versus Mental Imagery Training for Epidural Anesthesia Technical Achievement in Novice Anesthesiology Residents: A Randomized Comparative Study. Anesthesia and Analgesia, 2016, 122, 1516-1523.	2.2	12
59	A parametric model for long-term follow-up data from phase III breast cancer clinical trials. Statistics in Medicine, 2003, 22, 339-352.	1.6	11
60	Study protocol for targeted interventions to prevent chronic low back pain in high-risk patients: A multi-site pragmatic cluster randomized controlled trial (TARGET Trial). Contemporary Clinical Trials, 2019, 82, 66-76.	1.8	11
61	Efficacy of vagus nerve stimulation for drug-resistant epilepsy in children age six and younger. Epilepsy and Behavior, 2020, 112, 107373.	1.7	11
62	Prognostic impact of the 21-gene recurrence score (RS)Âon disease-free and overall survival of node-positive, ER-positive breast cancer patients (pts)Âtreated with adjuvantÂchemotherapy: Results from NSABPÂB-28 Journal of Clinical Oncology, 2012, 30, 1-1.	1.6	11
63	Reporting of cause-specific treatment effects in cancer clinical trials with competing risks: A systematic review. Contemporary Clinical Trials, 2012, 33, 920-924.	1.8	10
64	Nonparametric inference on causeâ€specific quantile residual life. Biometrical Journal, 2013, 55, 68-81.	1.0	10
65	Frailty modelling approaches for semi-competing risks data. Lifetime Data Analysis, 2020, 26, 109-133.	0.9	10
66	Elevated NT-Pro-Brain Natriuretic Peptide Level Is Independently Associated with All-Cause Mortality in HIV-Infected Women in the Early and Recent HAART Eras in the Women's Interagency HIV Study Cohort. PLoS ONE, 2015, 10, e0123389.	2.5	10
67	Application of Smoothing Methods to Evaluate Treatment-Prognostic Factor Interactions in Breast Cancer Data. Cancer Investigation, 2006, 24, 288-293.	1.3	9
68	Median Tests for Censored Survival Data; a Contingency Table Approach. Biometrics, 2012, 68, 983-989.	1.4	9
69	Comparison of traditional and closed loop vagus nerve stimulation for treatment of pediatric drug-resistant epilepsy: A propensity-matched retrospective cohort study. Seizure: the Journal of the British Epilepsy Association, 2022, 94, 74-81.	2.0	9
70	Comparison of various statistical methods for detecting disease outbreaks. Computational Statistics, 2010, 25, 603-617.	1.5	8
71	Bayesian nonparametric inference on quantile residual life function: Application to breast cancer data. Statistics in Medicine, 2012, 31, 1972-1985.	1.6	7
72	Development and Modification of an Outcome Measure to Follow Symptoms of Children with Sinusitis. Journal of Pediatrics, 2019, 207, 103-108.e1.	1.8	5

#	Article	IF	CITATIONS
73	Comparative Effectiveness of Embedded Mental Health Services in Pain Management Clinics vs Standard Care. Pain Medicine, 2020, 21, 978-991.	1.9	5
74	Stationary Versus Agitated Storage of Whole Blood During Acute Normovolemic Hemodilution. Anesthesia and Analgesia, 2014, 118, 264-268.	2.2	4
75	Competing events and costs of clinical trials: Analysis of a randomized trial in prostate cancer. Radiotherapy and Oncology, 2015, 115, 114-119.	0.6	4
76	Inference on win ratio for cluster-randomized semi-competing risk data. Japanese Journal of Statistics and Data Science, 2021, 4, 1263.	1.2	4
77	Cause-specific quantile residual life regression. Statistical Methods in Medical Research, 2017, 26, 1912-1924.	1.5	3
78	NSABP B-47: A randomized phase III trial of adjuvant therapy comparing chemotherapy alone to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer Journal of Clinical Oncology, 2013, 31, TPS1139-TPS1139.	1.6	3
79	Nonparametric Inference on Quantile Lost Lifespan. Biometrics, 2017, 73, 252-259.	1.4	2
80	Causeâ€specific quantile regression on inactivity time. Statistics in Medicine, 2021, 40, 1811-1824.	1.6	2
81	Quantile regression on inactivity time. Statistical Methods in Medical Research, 2021, 30, 1332-1346.	1.5	2
82	Statistical analysis in cancer clinical trials. Anti-Cancer Drugs, 2008, 19, S9-S10.	1.4	1
83	Identifying Predictors of Recommendations for and Participation in Multimodal Nonpharmacological Treatments for Chronic Pain Using Patient-Reported Outcomes and Electronic Medical Records. Pain Medicine, 2020, 21, 3574-3584.	1.9	1
84	Efficiency of Log-Rank Test Under Dependent Censorship. Communications in Statistics - Theory and Methods, 2003, 32, 1197-1211.	1.0	0
85	A note on the asymptotic relative efficiency of estimators from the additive hazards model. Journal of Statistical Planning and Inference, 2009, 139, 4231-4239.	0.6	0
86	Reply to J.J. Dignam. Journal of Clinical Oncology, 2011, 29, 4470-4470.	1.6	0
87	Optimal inferences for proportional hazards model with parametric covariate transformations. Annals of the Institute of Statistical Mathematics, 2012, 64, 715-736.	0.8	0
88	Reply to V. Pitini et al. Journal of Clinical Oncology, 2013, 31, 2225-2225.	1.6	0
89	Design, Implementation, and Interpretation of Clinical Trials. , 2010, , 585-625.		0
90	Design, Implementation, and Interpretation of Clinical Trials. , 2016, , 601-635.		0

Design, Implementation, and Interpretation of Clinical Trials. , 2016, , 601-635. 90

6